scholarly journals Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

2020 ◽  
Vol 61 (8) ◽  
pp. 1850-1859
Author(s):  
Katja Weisel ◽  
Meletios Dimopoulos ◽  
Philippe Moreau ◽  
Munci Yagci ◽  
Alessandra Larocca ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document